Ready-made stem cell therapies for pets could be coming | TechCrunch https://t.co/ukOEqmlBkX ...

New law goes into effect on July 1 authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the door to physicians' use of investigational stem cell therapies in the state in orthopedics, wound care, and pain manag ...

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa's transition from research to clinical-stage development. This come ...

Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the "SPA") entered into on March 31, 2025 with certain accredited investors. The ...

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial.The analysis reviewed survival from the time of first symptom onset through parti ...